NAMUR, Belgium, March 13, 2017 /PRNewswire/ -- VolitionRx Limited (NYSE MKT: VNRX) announced today that members of its senior management team and Board of Directors, including Chief Executive Officer, Cameron Reynolds, will ring the closing bell at the New York Stock Exchange (NYSE) on Monday, March 13, 2017 at 4 p.m. U.S. Eastern Daylight Time (EDT). This event recognises the Company's recent announcement of a CE mark for its Nu.Q^TM Colorectal Cancer Screening Triage Test.

The bell-ringing at the NYSE will be preceded earlier that day by a bell ringing at Trinity Church Wall Street led by Volition's Chairman, Dr. Martin Faulkes. Dr. Faulkes, a keen ringer, donated and installed the 12 bells at Trinity Church Wall Street in 2006. This is the first 12-bell change-ringing installation in the United States, and therefore, offers a unique bell-ringing experience.  At 10:00 am EDT on Monday, March 13^th, Dr. Faulkes, along with 11 Volition shareholders, will attempt to ring a peal of Nu.Q^TM Alliance Maximus which has been composed to celebrate Volition's first product, the Nu.Q^TM Colorectal Cancer Screening Triage Test. Volition received CE Marking on the Nu.Q^TM Colorectal Cancer Screening Triage Test in December 2016 and is currently marketing this novel blood test in Europe.

Speaking about the bell-ringing, Cameron Reynolds, CEO of Volition said: "We are very pleased to be at the NYSE at this very exciting time for Volition. We are coming to market with a diagnostic cancer test that we believe meets a pressing and immediate need in many European countries. Being able to offer healthcare systems a simple and easy to use blood test, which may be used to triage FIT positive populations for colorectal cancer, has the potential to make a significant and positive difference for their national colorectal cancer screening programs."

The New York Stock Exchange will stream the closing bell ringing live on its website at www.nyse.com/bell at 4 pm EDT. A video of the event will also be archived on that page after the live stream.

About Volition

Volition is a multi-national life sciences company developing simple, easy to use blood-based cancer tests to accurately diagnose a range of cancers. The tests are based on the science of Nucleosomics^®, which is the practice of identifying and measuring nucleosomes in the bloodstream or other bodily fluid -- an indication that disease is present.

As cancer screening programs become more and more widespread, our products aim to help to diagnose a range of cancers quickly, simply, accurately and cost effectively. Early diagnosis has the potential to not only prolong the life of patients, but also to improve their quality of life.

Volition's research and development activities are currently centered in Belgium, with additional offices in London, New York, and Singapore, as the company focuses on bringing its diagnostic products to market first in Europe, then in the U.S. and ultimately, worldwide.

For more information about Volition, visit Volition's website (http://www.volitionrx.com) or connect with us via:

Twitter: https://twitter.com/volitionrx

LinkedIn: https://www.linkedin.com/company/volitionrx

Facebook: https://www.facebook.com/VolitionRx/

YouTube: https://www.youtube.com/user/VolitionRx 

The contents found at Volition's website address, Twitter, LinkedIn, Facebook, and YouTube are not incorporated by reference into this document and should not be considered part of this document.  The addresses for Volition's website, Twitter, LinkedIn, Facebook, and YouTube are included in this document as inactive textual references only.

Media / Investor Contacts

 

 

Safe Harbor Statement

Statements in this press release may be "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that concern matters that involve risks and uncertainties that could cause actual results to differ materially from those anticipated or projected in the forward-looking statements. Words such as "expects," "anticipates," "intends," "plans," "aims," "targets," "believes," "seeks," "estimates," "optimizing," "potential," "goal," "suggests," "could," "would," "should," "may," "will" and similar expressions identify forward-looking statements. These forward-looking statements relate to the effectiveness of the Company's bodily-fluid-based diagnostic tests as well as the Company's ability to develop and successfully commercialize such test platforms for early detection of cancer. The Company's actual results may differ materially from those indicated in these forward-looking statements due to numerous risks and uncertainties. For instance, if we fail to develop and commercialize diagnostic products, we may be unable to execute our plan of operations. Other risks and uncertainties include the Company's failure to obtain necessary regulatory clearances or approvals to distribute and market future products in the clinical IVD market; a failure by the marketplace to accept the products in the Company's development pipeline or any other diagnostic products the Company might develop; the Company will face fierce competition and the Company's intended products may become obsolete due to the highly competitive nature of the diagnostics market and its rapid technological change; and other risks identified in the Company's most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q, as well as other documents that the Company files with the Securities and Exchange Commission. These statements are based on current expectations, estimates and projections about the Company's business based, in part, on assumptions made by management. These statements are not guarantees of future performance and involve risks, uncertainties and assumptions that are difficult to predict. Forward-looking statements are made as of the date of this release, and, except as required by law, the Company does not undertake an obligation to update its forward-looking statements to reflect future events or circumstances.

Nucleosomics®, NuQ®, Nu.Q^TM and HyperGenomics® and their respective logos are trademarks and/or service marks of VolitionRx Limited and its subsidiaries. All other trademarks, service marks and trade names referred to in this press release are the property of their respective owners.

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/volitionrx-limited-to-ring-the-new-york-stock-exchange-closing-bell-on-monday-march-13th-at-4-pm-eastern-daylight-time-300422244.html

SOURCE VolitionRx Limited